المؤلفون: Dittrich T; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital.; Amyloidosis Center, Heidelberg University Hospital.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, Heidelberg University Hospital., Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg., Kimmich C; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital.; Amyloidosis Center, Heidelberg University Hospital., Siepen FAD; Amyloidosis Center, Heidelberg University Hospital.; Department of Internal Medicine III, Division of Cardiology, Heidelberg University Hospital, Germany., Veelken K; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital.; Amyloidosis Center, Heidelberg University Hospital., Kristen AV; Amyloidosis Center, Heidelberg University Hospital.; Department of Internal Medicine III, Division of Cardiology, Heidelberg University Hospital, Germany., Bochtler T; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital.; Amyloidosis Center, Heidelberg University Hospital.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, Heidelberg University Hospital., Katus HA; Department of Internal Medicine III, Division of Cardiology, Heidelberg University Hospital, Germany., Müller-Tidow C; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital.; Amyloidosis Center, Heidelberg University Hospital., Hegenbart U; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital stefan.schoenland@med.uni-heidelberg.de ute.hegenbart@med.uni-heidelberg.de.; Amyloidosis Center, Heidelberg University Hospital., Schönland SO; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital stefan.schoenland@med.uni-heidelberg.de ute.hegenbart@med.uni-heidelberg.de.; Amyloidosis Center, Heidelberg University Hospital.

المصدر: Haematologica [Haematologica] 2019 Jul; Vol. 104 (7), pp. 1451-1459. Date of Electronic Publication: 2019 Jan 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Glomerular Filtration Rate*, Atrial Fibrillation/*physiopathology , Biomarkers/*blood , Immunoglobulin Light-chain Amyloidosis/*classification , Immunoglobulin Light-chain Amyloidosis/*pathology , Renal Insufficiency/*physiopathology, Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin Light-chain Amyloidosis/blood ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Risk Factors

المؤلفون: Hegenbart U; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany ute.hegenbart@med.uni-heidelberg.de., Bochtler T; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Becker N; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Kimmich C; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany., Kristen AV; Division of Cardiology, University of Heidelberg, Germany., Beimler J; Division of Nephrology, University of Heidelberg, Germany., Hund E; Department of Neurology, University of Heidelberg, Germany., Zorn M; Division of Clinical Chemistry, University of Heidelberg, Germany., Freiberger A; Coordination Center for Clinical Trials, KKS, Heidelberg, Germany., Gawlik M; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany., Goldschmidt H; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany., Hose D; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany., Jauch A; Institute of Human Genetics, University Heidelberg, Germany., Ho AD; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany., Schönland SO; Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany.; Division of Cardiology, University of Heidelberg, Germany.

المصدر: Haematologica [Haematologica] 2017 Aug; Vol. 102 (8), pp. 1424-1431. Date of Electronic Publication: 2017 May 18.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Immunoglobulin Light-chain Amyloidosis/*drug therapy, Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin Light-chain Amyloidosis/mortality ; Lenalidomide ; Male ; Melphalan ; Middle Aged ; Remission Induction/methods ; Survival Analysis ; Thalidomide/analogs & derivatives